Innovest Global, Inc. ($IVST) Ready to Enter Healthcare Sector, As Global Health Spending Projected to Reach $8.7 Trillion By 2020 - Spotlight Growth
Sacramento, CA , April 10, 2018 (GLOBE NEWSWIRE) -- A new report and video has been published on Innovest Global, Inc. (OTC PINK: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, biotech, commercial energy, business-to-business distribution, national call center and auto sales.
The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers the global outlook for the healthcare sector.
Deloitte: 656 Million People Or 11.5% Of Global Population Is Aged 65 Or Older
Technological advancements have aided humanity across all aspects of our lives. One of the key benefits of greater technological capabilities is ability to develop more effective healthcare treatments. After all, health and wellness are key components to any thriving civilization. Greater abilities to extend human life can be witnessed through the statistic that 656 million people, or around 11.50% of total world population, is now aged 65 years or older.
According to Deloitte’s 2018 Global Life Sciences Outlook report, global healthcare spending is forecast to reach $8.7 trillion by 2020, compared to $7 trillion in 2015. The market research firm credits the spending increase on aging and expanding populations, growing emerging markets, advancements in medical technology, and rising labor costs.
However, the rising capabilities of medical technology are not expected to stop the growth of ailments and deadly diseases. For example, Deloitte estimates that diabetes will affect around 642 million people by 2040 thanks to rapid urbanization, diet changes, increasingly sedentary lifestyles, and skyrocketing obesity rates.
On a more positive note, medical technology (Medtech) is seen as another strong area of the healthcare sector, which is forecast to reach $521.9 billion by 2022. Overall, researchers see in virtro diagnostics as the key driver and largest segment of medtech moving forward.
According to the American Brain Tumor Association, an estimated 80,000 new cases of primary brain tumors will be diagnosed this year. Another 17,000 people are estimated to lose their battle with a primary brain or CNS tumor this year.
According to GBI Research, global revenues for the cancer vaccine market are forecast to grow from $2.5 billion in 2015 to $7.5 billion in 2022, which represents a compound annual growth rate (CAGR) of 16.93%.
Innovest Recently Signs LOI to Acquire 20% Stake in StemVax Therapeutics, A Brain Cancer Vaccine Developer
Innovest Global recently announced that it has signed a Letter of Intent to acquire a 20% stake in StemVax Therapeutics, a biotechnology company that is currently developing a brain cancer vaccine.
The StemVax Glioblast (SVX-GB) cancer vaccine is being designed and formulated to help restore a patient’s immune system in order to fight off existing cancer cells within the body.
The vaccine is designed to fight against glioblastoma brain cancers, which is the same type of tumor that is currently affecting Arizona Senator John McCain.
In other news, Innovest also recently announced that its Innovest Energy Group has completed the previously-announced LOI acquisition of H.P. Technologies, an energy procurement company that is generating annual revenues of $1.2 million. Furthermore, H.P.’s owner, Dennis Giancola, has joined the Innovest Energy Group division.
Entering into the second quarter, Innovest Global is now generating baseline quarterly revenues of around $800,000, just from its Commercial & Industrial Energy division alone. This comes as management is scheduled to officially launch its Biotech & Health Sciences division this Spring.
Management announced in its March shareholder update that it has engaged NMS, Inc. to conduct a two-year audit on the company’s financials. The PCAOB-compliant firm has a strong 30-year track record of success and has a staff of 40 employees. This effectively begins the company’s plan to uplist to higher exchanges, such as the OTCQX and eventually the NASDAQ or NYSE.
Innovest Global, Inc. was also recently featured on the inaugural episode of Spotlight Growth Live, a video web series that focuses on emerging growth companies.
For more information on Innovest Global, Inc.,
please visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/04/...l-health...
SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/
Sacramento, CA , April 10, 2018 (GLOBE NEWSWIRE) -- A new report and video has been published on Innovest Global, Inc. (OTC PINK: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across telehealth, biotech, commercial energy, business-to-business distribution, national call center and auto sales.
The report provides an overview of Innovest Global, Inc., its subsidiaries, financials, industry analysis and more. The content also covers the global outlook for the healthcare sector.
Deloitte: 656 Million People Or 11.5% Of Global Population Is Aged 65 Or Older
Technological advancements have aided humanity across all aspects of our lives. One of the key benefits of greater technological capabilities is ability to develop more effective healthcare treatments. After all, health and wellness are key components to any thriving civilization. Greater abilities to extend human life can be witnessed through the statistic that 656 million people, or around 11.50% of total world population, is now aged 65 years or older.
According to Deloitte’s 2018 Global Life Sciences Outlook report, global healthcare spending is forecast to reach $8.7 trillion by 2020, compared to $7 trillion in 2015. The market research firm credits the spending increase on aging and expanding populations, growing emerging markets, advancements in medical technology, and rising labor costs.
However, the rising capabilities of medical technology are not expected to stop the growth of ailments and deadly diseases. For example, Deloitte estimates that diabetes will affect around 642 million people by 2040 thanks to rapid urbanization, diet changes, increasingly sedentary lifestyles, and skyrocketing obesity rates.
On a more positive note, medical technology (Medtech) is seen as another strong area of the healthcare sector, which is forecast to reach $521.9 billion by 2022. Overall, researchers see in virtro diagnostics as the key driver and largest segment of medtech moving forward.
According to the American Brain Tumor Association, an estimated 80,000 new cases of primary brain tumors will be diagnosed this year. Another 17,000 people are estimated to lose their battle with a primary brain or CNS tumor this year.
According to GBI Research, global revenues for the cancer vaccine market are forecast to grow from $2.5 billion in 2015 to $7.5 billion in 2022, which represents a compound annual growth rate (CAGR) of 16.93%.
Innovest Recently Signs LOI to Acquire 20% Stake in StemVax Therapeutics, A Brain Cancer Vaccine Developer
Innovest Global recently announced that it has signed a Letter of Intent to acquire a 20% stake in StemVax Therapeutics, a biotechnology company that is currently developing a brain cancer vaccine.
The StemVax Glioblast (SVX-GB) cancer vaccine is being designed and formulated to help restore a patient’s immune system in order to fight off existing cancer cells within the body.
The vaccine is designed to fight against glioblastoma brain cancers, which is the same type of tumor that is currently affecting Arizona Senator John McCain.
In other news, Innovest also recently announced that its Innovest Energy Group has completed the previously-announced LOI acquisition of H.P. Technologies, an energy procurement company that is generating annual revenues of $1.2 million. Furthermore, H.P.’s owner, Dennis Giancola, has joined the Innovest Energy Group division.
Entering into the second quarter, Innovest Global is now generating baseline quarterly revenues of around $800,000, just from its Commercial & Industrial Energy division alone. This comes as management is scheduled to officially launch its Biotech & Health Sciences division this Spring.
Management announced in its March shareholder update that it has engaged NMS, Inc. to conduct a two-year audit on the company’s financials. The PCAOB-compliant firm has a strong 30-year track record of success and has a staff of 40 employees. This effectively begins the company’s plan to uplist to higher exchanges, such as the OTCQX and eventually the NASDAQ or NYSE.
Innovest Global, Inc. was also recently featured on the inaugural episode of Spotlight Growth Live, a video web series that focuses on emerging growth companies.
For more information on Innovest Global, Inc.,
please visit http://innovestglobal.com and http://spotlightgrowth.com/index.php/2018/04/...l-health...
SpotlightGrowth.com is a digital hub for micro-caps, small-caps, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small cap companies.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand five hundred dollars cash and fifty thousand restricted shares for the creation and dissemination of this content.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/
